Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

NKGN

NKGen Biotech Inc

Jun 18 • 04:00PM ET

1.19

Dollar change -0.10
Percentage change -7.75	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.37	Insider Own	52.88%	Shs Outstand	21.89M	Perf Week	-15.60%
Market Cap	29.62M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	11.73M	Perf Month	6.25%
Income	-74.00M	PEG	-	EPS next Q	-	Inst Own	9.71%	Short Float	5.12%	Perf Quarter	-43.87%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	12.77%	Short Ratio	0.31	Perf Half Y	-64.58%
Book/sh	-2.00	P/B	-	EPS next Y	-	ROA	-73.13%	Short Interest	0.60M	Perf Year	-88.39%
Cash/sh	0.01	P/C	105.78	EPS next 5Y	-	ROE	-118.66%	52W Range	0.78 - 12.88	Perf YTD	-56.73%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-90.76%	Beta	0.59
Dividend TTM	-	Quick Ratio	0.04	Sales past 5Y	-50.00%	Gross Margin	-	52W Low	52.53%	ATR (14)	0.17
Dividend Ex-Date	-	Current Ratio	0.04	EPS Y/Y TTM	-3303.01%	Oper. Margin	0.00%	RSI (14)	40.41	Volatility	10.19% 15.13%
Employees	63	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-1486.44%	Payout	-	Rel Volume	0.07	Prev Close	1.29
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	1.93M	Price	1.19
SMA20	-21.37%	SMA50	-15.32%	SMA200	-60.50%	Trades		Volume	132,233	Change	-7.75%

Jun-12-24 01:05PM	NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 (GlobeNewswire) -8.51%
Jun-03-24 08:05AM	NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024 (GlobeNewswire) -6.59%
May-23-24 05:05PM	NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -23.66%
May-21-24 09:53AM	NKGN Stock Earnings: NKGen Biotech Reported Results for Q1 2024 (InvestorPlace)
May-20-24 11:41AM	NKGN Stock Alert: The Alzheimer's News That Has NKGen Biotech Soaring Today (InvestorPlace) +52.68%
08:05AM	NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease (GlobeNewswire)
May-16-24 08:05AM	NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition (GlobeNewswire)
Apr-29-24 08:00AM	NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinsons Disease (GlobeNewswire)
Apr-25-24 04:05PM	NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit (GlobeNewswire) +15.79% -18.69%
Apr-24-24 04:45PM	NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) -7.57%
Apr-18-24 04:05PM	NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit (GlobeNewswire) -16.50% +28.60%
Apr-16-24 11:53PM	NKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023 (InvestorPlace) -14.88%
Apr-11-24 08:05AM	NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs (GlobeNewswire)
Mar-25-24 04:05PM	NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conference (GlobeNewswire) -6.90% -11.11%
Mar-06-24 07:52AM	Why Is NKGen Biotech (NKGN) Stock Up 62% Today? (InvestorPlace) +112.30%
Mar-04-24 08:00AM	NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global Conference (GlobeNewswire)
Feb-07-24 08:57AM	Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies (News Direct)
Dec-29-23 07:30AM	NKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial (News Direct) -10.42%
Dec-28-23 04:05PM	NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer's Disease (GlobeNewswire) -7.53%
Dec-27-23 08:00AM	NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer's Disease (GlobeNewswire) +17.73%
Nov-14-23 04:48PM	NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights (GlobeNewswire)
Oct-26-23 08:00AM	NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire) +8.00%
Oct-24-23 10:53AM	NKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimers Disease Treatment. (News Direct) +16.16%
08:00AM	NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimers Disease (GlobeNewswire)
Oct-19-23 08:00AM	NKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference (GlobeNewswire)
Oct-17-23 08:00AM	NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023 (GlobeNewswire)
Oct-11-23 08:00AM	NKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023 (GlobeNewswire)

NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Song Paul Y.	Chief Executive Officer	Dec 07 '23	Buy	3.29	76	250	171,121	Dec 07 05:23 PM
Song Paul Y.	Chief Executive Officer	Dec 06 '23	Buy	3.32	75	250	171,045	Dec 07 05:23 PM
Song Paul Y.	Chief Executive Officer	Dec 05 '23	Buy	3.33	105	350	170,969	Dec 05 03:51 PM
Graf James A	Interim CFO	Dec 04 '23	Buy	3.19	450	1,436	693	Dec 05 03:50 PM
Song Paul Y.	Chief Executive Officer	Dec 04 '23	Buy	3.07	163	500	170,864	Dec 05 03:51 PM
Graf James A	Interim CFO	Dec 01 '23	Buy	3.35	220	737	243	Dec 05 03:50 PM
Song Paul Y.	Chief Executive Officer	Nov 27 '23	Buy	2.88	244	701	170,701	Nov 28 04:10 PM
Song Paul Y.	Chief Executive Officer	Nov 22 '23	Buy	2.85	53	150	170,458	Nov 22 05:53 PM
Song Paul Y.	Chief Executive Officer	Nov 21 '23	Buy	2.80	100	280	170,405	Nov 22 05:53 PM
Graf James A	Interim CFO	Nov 21 '23	Buy	2.92	13	38	23	Nov 22 05:55 PM
Graf James A	Interim CFO	Nov 20 '23	Buy	2.94	10	29	10	Nov 22 05:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

NKGN

NKGen Biotech Inc

Upgrade your FINVIZ experience